Evidence map›Paper›PMID 42227742›Full record

ReviewJournal of virology2026

Structural overview of lyssavirus glycoproteins, antibodies, and receptors.

Heather M Callaway

Abstract readReview
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Heather M CallawayDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, USA.ORCID 0000-0003-4003-3854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rabies virus is the most lethal virus ever discovered and remains a global health threat despite vaccines and post-exposure treatment. In addition to rabies, there are also 17 other lyssaviruses, several of which have already crossed species barriers to infect humans and cause the same clinical disease as the rabies virus. While effective in preventing rabies infection, current rabies vaccines do not provide long-lasting protection or elicit antibodies that are broadly protective against both rabies and related lyssaviruses. Efforts to improve rabies vaccines to elicit a uniform, longer-lasting, and more broadly neutralizing antibody response would benefit from structure-guided design, where high-resolution protein structures are used to engineer vaccine antigens. In the last 6 years, the first high-resolution structures of lyssavirus glycoproteins have become available, giving new insights into how these viruses interact with host antibodies and receptors, and making structure-guided antigen design feasible. This review encompasses recent findings in lyssavirus glycoprotein structure, interactions with neutralizing antibodies, and interactions with potential cellular receptors, with an emphasis on the rabies virus.

Indexed as

Antibodies, ViralGlycoproteinsLyssavirusReceptors, VirusAnimalsAntibodies, NeutralizingHumansModels, MolecularProtein ConformationRabiesRabies VaccinesRabies virusAntibodies, NeutralizingAntibodies, ViralGlycoproteinsRabies VaccinesReceptors, Viruslyssavirusesneutralizing antibodiesrabiesreceptor bindingstructural biologystructures

Identifiers

PMID42227742
PMCPMC13288784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.